The Use of Morphology-Directed Targeted Immunosuppression With Dupilumab in Cutaneous Immunotherapy Related Adverse Events. Dulmage B, Kaffenberger BH. Int J Dermatol 2025 Jul 17. doi: 10.1111/ijd.17956.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dulmage B, Kaffenberger BH. The Use of Morphology-Directed Targeted Immunosuppression With Dupilumab in Cutaneous Immunotherapy Related Adverse Events. Int J Dermatol 2025 Jul 17. doi: 10.1111/ijd.17956.
PMID: 40676779